



M K PROTEINS

Date: 23.05.2025

To
The Manager
Listing Compliance
Bombay Stock Exchange Limited
P.J Towers, Dalal Street,
Mumbai-400 001
Maharashtra, India
SCRIP CODE: 543919

To
The Manager
Listing Compliance
National Stock Exchange of India
Limited (NSE)
Exchange Plaza, Bandra Kurla Complex,
Bandra East, Mumbai - 400051
NSE SYMBOL: MKPL

Subject: Outcome of the Board Meeting held today i.e. 23rd May, 2025

Dear Sir/Madam,

Pursuant to the Regulations 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform that the Board of Directors of the Company at its meeting held today i.e. on Friday, May 23, 2025, *inter alia*, considered and approved the following matters:

1. Audited Standalone Financial Results of the Company for the Quarter and Year ended on 31st March, 2025 together with a Statement of Cash Flow, Statement of Assets and Liabilities for the same period;
2. Auditors Report on the said Financial Results;
3. Declaration regarding unmodified opinion on Audited Standalone Financial Results under Regulation 33(3)(d) of the Securities & Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2016;
4. Appointment of M/s. K. K. Sinha & Associates, as Cost Auditors of the Company for the period 2025-26.

Details as required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November, 2024, amended from time to time are enclosed as Annexure.

5. Appointment of M/s. Jayant Bansal & Co., Chartered Accountants as Internal Auditor of the Company for the Financial Year 2025-26. Details as required under Regulation 30 of SEBI (LODR) Regulations, 2015 read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November, 2024, are enclosed as Annexure.

M. K. Proteins Limited

Naraingarh Road, Village Garnala, Ambala City(Haryana), India - 134003

T : 0171-2679358 | W: www.mkproteins.in | E: compliancemkproteins@gmail.com

CIN : L15500HR2012PLC046239 | ISIN : INE964W01021



M K PROTEINS

6. The appointment of M/s. J.P. Jagdev & Co., Company Secretaries, as Secretarial Auditor of the Company to conduct the Secretarial Audit for the financial year 2024-25 and to issue the Secretarial Audit Report thereon.

The disclosure of information pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 is attached as Annexure-B.



7. Related Party Transactions for the Half Year ended 31.03.2025;

The meeting of the Board of Directors commenced at 04:00 P.M. and concluded at 5:00 P.M.

You are requested to take the same on your record.

Thanking You,

Yours Faithfully,
FOR M K PROTEINS LIMITED



Parmod Kumar
Managing Director
DIN: 00126965

M. K. Proteins Limited

Naraingarh Road, Village Garnala, Ambala City(Haryana), India - 134003

T : 0171-2679358 | W: www.mkproteins.in | E: compliancemkproteins@gmail.com

CIN : L15500HR2012PLC046239 | ISIN : INE964W01021




M K PROTEINS

Annexure A

Details under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read along with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November, 2024.

| S. No. | Particulars | Cost Auditor |
|--------|---|---|
| | | M/s. K. K. Sinha & Associates |
| 1. | Reason for change viz. appointment, resignation, removal, death or otherwise; | Re-appointment |
| 2. | Date of appointment/cessation (as applicable) & term of appointment; | Date of Appointment: 23/05/2025 Term of Appointment: Financial Year 2025-26 |
| 3. | Brief Profile (in case of appointment) | M/s K. K. Sinha & Associates is a well-established name in Income Tax Consultancy, Goods and Service Tax Consultants, Product Pricing and Cost estimates, Cost Audit and Compliance Reports, Cost Accounting Records, Tax Deduction at Source Returns and cases in Appeals and liaison with departments and Central Excise & Service Tax Consultancy many other services. |



M. K. Proteins Limited

Naraingarh Road, Village Garnala, Ambala City(Haryana), India - 134003

T : 0171-2679358 | W: www.mkproteins.in | E: compliancemkproteins@gmail.com

CIN : L15500HR2012PLC046239 | ISIN : INE964W01021




M K PROTEINS

Annexure-B

DETAILS UNDER REGULATION 30 OF SECURITIES AND EXCHANGE BOARD OF INDIA (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015 READ WITH SEBI CIRCULAR SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023

| S. No. | Particulars | Details |
|--------|---|--|
| 1. | Reason for change viz. appointment, resignation, removal, or otherwise | Appointment: To comply with the Companies Act, 2013 and the requirements under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. |
| 2. | Date of appointment/cessation & term of appointment | Date: May 23, 2025 M/s. J.P. Jagdev & Co., Company Secretaries is appointed as Secretarial Auditor of the Company for the F.Y 2024-25. |
| 3. | Brief Profile (in case of appointment) | Name of Secretarial Auditor: M/s. J.P. Jagdev & Co, Company Secretaries Email id: jpjncoin@gmail.com Office Address: 22-A, Kanshi Nager, Model Town, Ambala City-134003 HR Field of Experience: Mr. Jai Prakash Jagdev is a Company Secretary (M. No. 2469 & COP No. 2056), based in Ambala. He has vast experience in the field of Company Law, Secretarial Work, Due Diligence, SEBI Regulations etc. |
| 4. | Disclosure of relationships between directors (in case of appointment of a director). | NA |



M. K. Proteins Limited

Naraingarh Road, Village Garnala, Ambala City(Haryana), India - 134003

T : 0171-2679358 | W: www.mkproteins.in | E: compliancemkproteins@gmail.com

CIN : L15500HR2012PLC046239 | ISIN : INE964W01021



M K PROTEINS

(ii) Details of Internal Auditor

| S. No. | Particulars | Internal Auditor |
|--------|---|---|
| | | M/s. Jayant Bansal & Co. |
| 1. | Reason for change viz. appointment, resignation, removal, death or otherwise; | Appointment |
| 2. | Date of appointment/cessation (as applicable) & term of appointment; | Date of Appointment: 23/05/2025 Term of Appointment: Financial Year 2025-26 |
| 3. | Brief Profile (in case of appointment) | M/s Jayant Bansal & Co., Chartered Accountants (FRN: 004694N) Off. Address: 320, Mahesh Nagar, Ambala Cantt-133001 Mr. Jayant Bansal is a member of Institute of Chartered Accountants of India since 1987 and his firm M/s Jayant Bansal & Co., specializes in Statutory Audits, Internal Audits, and provides comprehensive tax advisory services to listed and unlisted companies and organisations. |
| 4. | Disclosure of relationships between directors (in case of appointment of a director). | NA |

M. K. Proteins Limited

Naraingarh Road, Village Garnala, Ambala City(Haryana), India - 134003

T : 0171-2679358 | W : www.mkproteins.in | E : compliancemkproteins@gmail.com

CIN : L15500HR2012PLC046239 | ISIN : INE964W01021



M K PROTEINS

Date:
23.05.2025

To
The Manager
Listing Compliance
Bombay Stock Exchange Limited
P.J Towers, Dalal Street,
Mumbai-400 001
Maharashtra, India
SCRIP CODE: 543919

To
The Manager
Listing Compliance
National Stock Exchange of India
Limited (NSE)
Exchange Plaza, Bandra Kurla Complex,
Bandra East, Mumbai - 400051
NSE SYMBOL: MKPL

Sub: Declaration under Regulation 33(3)(d) of the Securities & Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2016

Dear Sir/Madam,


I, Parmod Kumar, Managing Director of M/s M K Proteins Limited, having its Registered Office at Naraingarh Road, Vill. Garnala Ambala City-134003 HR, hereby declare that **M/s KRA&CO.**, Statutory Auditors of the Company have issued an Auditor Report with unmodified opinion on the Audited Standalone Financial Results of the Company for the Quarter and Year ended March 31, 2025.

This declaration is issued in compliance of Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended vide its Circular No. Cir CFD CMD 56 2016 dated May 27, 2016.

Thanking You,

Yours Faithfully,
For M K Proteins Limited

Parmod Kumar
Managing Director
DIN: 00126965



M. K. Proteins Limited

Naraingarh Road, Village Garnala, Ambala City(Haryana), India - 134003

T : 0171-2679358 | W: www.mkproteins.in | E: compliancemkproteins@gmail.com

CIN : L15500HR2012PLC046239 | ISIN : INE964W01021



INDEPENDENT AUDITOR'S REPORT ON THE AUDIT OF STANDALONE ANNUAL FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF M. K. PROTEINS LIMITED

Opinion

We have audited the accompanying standalone annual financial results of **M. K. PROTEINS LIMITED** ("the company") for the half year and year ended March 31, 2025 ("Standalone annual Financial results") attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone annual financial results:

- a. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- b. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting Standards and other accounting principles generally accepted in India of the net profit and other financial information for the half year and year ended March 31, 2025.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those Standards are further described in the "Auditor's Responsibilities for the Audit of the Standalone Financial Results" section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statement under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained by us is sufficient and appropriate to provide a basis for our opinion.

Management's and Board of Directors' Responsibilities for the Standalone Annual Financial Results

These standalone annual financial results have been prepared on the basis of the standalone annual financial statements.

The Company's Management and Board of Directors are responsible for the preparation of these standalone annual financial results that give a true and fair view of the net profit and other financial information in accordance with the recognition and measurement principles laid down in Accounting Standard prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and

maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone annual financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone annual financial results, the Management and Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Annual Financial Results

Our objectives are to obtain reasonable assurance about whether the standalone annual financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone annual financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone annual financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, Under Section 143(3) (i) of the Companies Act 2013, we are also responsible for expressing our opinion through a separate report on the complete set of financial statements on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Management and Board of Directors.
- Conclude on the appropriateness of the Management and Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone annual financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations, as amended, to the extent applicable.

For KRA & Co.

Chartered Accountants

(Firm Registration No.020266N)

Rajat Digitally
signed by
Goyal Rajat Goyal

Rajat Goyal

Partner

Membership No.: 503150

UDIN: 25503150BMJBZH8774

Place: New Delhi

Date: 23-05-2025

M. K. PROTEINS LIMITED


Regd. Office: Naraingarh Road, Village Garnala, Ambala City (Haryana), India - 134003

T: 0171-2679358 | W: www.mkproteins.in | E: compliancemkproteins@gmail.com

CIN: L15500HR2012PLC046239 | ISIN: INE964W01013

STATEMENT OF AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31ST MARCH 2025

| | | QUARTER ENDED | | | YEAR ENDED | |
|--|--|-------------------------|---------------------------|-------------------------|-------------------------|-------------------------|
| | | 31-03-2025 (AUDITED) | 31-12-2024 (UNAUDITED) | 31-03-2024 (AUDITED) | 31-03-2025 (AUDITED) | 31-03-2024 (AUDITED) |
| 1. Revenue | | | | | | |
| a) Revenue from Operation (Net) | | 13720.41 | 3947.88 | 8687.29 | 26770.60 | 24557.11 |
| b) Other Income | | 1.94 | 24.56 | 41.04 | 47.66 | 44.66 |
| Sub-Total "1" | | 13722.35 | 3972.44 | 8728.33 | 26818.26 | 24601.77 |
| 2. Expenditure | | | | | | |
| a) Cost of Material Consumed | | 11229.32 | 2003.69 | 11144.47 | 16674.36 | 20571.80 |
| b) Purchase of Stock-in-Trade | | 2343.13 | 1968.15 | 358.70 | 5149.41 | 3294.36 |
| c) Change in inventories of Finished Goods, Work-in-progress and Stock-in-Trade | | (1176.68) | (472.85) | (3985.10) | 2146.27 | (2223.11) |
| d) Employees Benefits Expenses | | 82.49 | 63.97 | 79.26 | 274.52 | 278.80 |
| e) Manufacturing, Operating and Other Expenses | | 776.29 | 205.26 | 247.67 | 1282.93 | 973.61 |
| f) Finance Costs | | 67.44 | 6.92 | 39.77 | 110.50 | 106.49 |
| g) Depreciation and Amortization Expenses | | 8.85 | 11.43 | 17.76 | 35.17 | 52.85 |
| Sub-Total "2" | | 13330.84 | 3786.57 | 7902.53 | 25673.16 | 23054.80 |
| 3 Profit/(Loss) before Exceptional, Extraordinary items and Tax [1 - 2] | | 391.51 | 185.87 | 825.80 | 1145.10 | 1546.97 |
| 4 Exceptional Items | | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 5 Profit/(Loss) before Extraordinary items and Tax [3 - 4] | | 391.51 | 185.87 | 825.80 | 1145.10 | 1546.97 |
| 6 Extraordinary Items | | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 7 Profit/(Loss) before Tax [5 - 6] | | 391.51 | 185.87 | 825.80 | 1145.10 | 1546.97 |
| 8 Tax Expenses | | | | | | |
| a) Provision for Current Tax | | 111.54 | 47.40 | 236.15 | 301.86 | 417.73 |
| b) Provision for Deferred Tax Liability/(Adjustment) | | 0.36 | 0.95 | 6.67 | 3.50 | 8.05 |
| c) Prior Year Taxes | | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sub-Total "8" | | 111.90 | 48.35 | 242.82 | 305.36 | 425.78 |
| 9 Profit/(Loss) for the Period from continuing operations [7 - 8] | | 279.61 | 137.52 | 582.98 | 839.74 | 1121.19 |
| 10 Profit/(Loss) for the period from Discontinuing operations before tax | | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 11 Tax expenses of Discontinuing operations | | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 12 Profit/(Loss) from Discontinuing operations (After Tax) [10 - 11] | | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 13 Profit/(Loss) for the period [9 + 12] | | 279.61 | 137.52 | 582.98 | 839.74 | 1121.19 |
| 14 Other Comprehensive Income net of taxes | | | | | | |
| a) (i) Amount of items that will not be reclassified to profit and loss | | (1.51) | 0.00 | (0.55) | (1.51) | (0.55) |
| (ii) Income Tax relating to items that will not be reclassified to profit and loss | | (0.38) | 0.00 | (0.14) | (0.38) | (0.14) |
| b) (i) Amount of items that will be reclassified to profit and loss | | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| (ii) Income Tax relating to items that will be reclassified to profit and loss | | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sub- Total "14" | | (1.13) | 0.00 | (0.41) | (1.13) | (0.41) |
| 15 Total comprehensive Income for the Period [13 + 14] | | 278.48 | 137.52 | 582.57 | 838.61 | 1120.78 |
| 16 Earnings per share | | | | | | |
| a) Earnings per Equity Share for continuing operations | | | | | | |
| Basic earnings/(Loss) per share from continuing operations | | 0.07 | 0.04 | 0.16 | 0.22 | 0.30 |
| Diluted earning/(Loss) per share from continuing operations | | 0.07 | 0.04 | 0.16 | 0.22 | 0.30 |
| b) Earnings per Equity Share for discontinuing operations | | | | | | |
| Basic earning/(Loss) per share from discontinuing operations | | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Diluted earning/(Loss) per share from discontinuing operations | | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |



| | | | | | | |
|----|---|---------|---------|---------|---------|---------|
| c) | Earnings per Equity Share | | | | | |
| | Basic earning/(Loss) per share from continuing and discontinuing operations | 0.07 | 0.04 | 0.16 | 0.22 | 0.30 |
| | Diluted earning/(Loss) per share from continuing and discontinuing operations | 0.07 | 0.04 | 0.16 | 0.22 | 0.30 |
| 17 | Details of Equity Share Capital | | | | | |
| | Paid-up Equity Share Capital | 3753.72 | 3753.72 | 3753.72 | 3753.72 | 3753.72 |
| | Face value of Equity Share Capital | 1 | 1 | 1 | 1 | 1 |
| 18 | Other Equity [Reserves] | 3192.86 | - | 2353.84 | 3192.86 | 2353.84 |


Note:

1. The above mentioned audited results were reviewed by the Audit Committee and approved by the Board of Directors of the Company at its meeting held on 23rd May 2025.
2. The Statutory auditors of the Company have carried out an audit of the above results for the quarter and year to date ended March 31, 2025. The Auditors' opinion on quarterly and year to date standalone financial results of the company is unmodified.
3. Previous period/year figures have been regrouped / rearranged, wherever necessary, to confirm with the current period classification.
4. The Company is engaged in single business activity (i.e. Manufacturing of Vegetable Refined oil) and there is no separate reportable segment.
5. The financial results of the Company have been prepared in accordance with Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 read with relevant rules there under and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI circular dated July 5, 2016.
6. The figures for the quarter ended March 31, 2025 and March 31, 2024 are the balancing figures between audited figures in respect of the full financial year and the year-to-date published figures up to the quarter ended December 31, 2024 and December 31, 2023 respectively.
7. Disclosure of assets and liabilities as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the year ended 31st March, 2025 is given as per Annexure "I" attached.

Place: Ambala

Dated: 23-05-2025

For and on behalf of the board



(Parmod Kumar)
Managing Director
DIN: 00126965

M. K. PROTEINS LIMITED

Regd. Office: Naraingarh Road, Village Garnala, Ambala City (Haryana), India - 134003

T: 0171-2679358 | W: www.mkproteins.in | E: compliancemkproteins@gmail.com

CIN: L15500HR2012PLC046239 | ISIN: INE964W01013

ANNEXURE "I"

STATEMENT OF ASSETS AND LIABILITIES AS AT 31ST MARCH 2025 IS GIVEN BELOW: -


| | PARTICULARS | AS AT 31-03-2025 (AUDITED) | AS AT 31-03-2024 (AUDITED) |
|----------|-------------------------------------|----------------------------------|----------------------------------|
| A | ASSETS | | |
| 1 | Non-Current Assets | | |
| | -Property, Plant and Equipment | 285.74 | 189.69 |
| | -Capital Work-in-Progress | 665.54 | 590.00 |
| | -Right of Use Assets | 82.23 | 87.51 |
| | -Intangible assets | 0.00 | 0.00 |
| | <u>Financial Assets</u> | | |
| | -Investments | 0.00 | 0.00 |
| | -Other financial assets | 34.26 | 44.50 |
| | Deferred Tax Assets (net) | 34.34 | 37.46 |
| | Other non-current assets | 103.30 | 91.34 |
| | Sub-Total "1" Non-Current Assets | 1205.41 | 1040.50 |
| 2 | Current Assets | | |
| | -Inventories | 11132.48 | 7927.25 |
| | <u>Financial Assets</u> | | |
| | -Investments | 0.00 | 0.00 |
| | -Trade Receivables | 140.33 | 357.27 |
| | -Cash and Cash Equivalents | 3.38 | 9.23 |
| | -Other Financial assets | 0.00 | 0.00 |
| | Other Current Assets | 575.37 | 290.35 |
| | Sub-Total "2" Current Assets | 11851.56 | 8584.41 |
| | TOTAL ASSETS | 13056.97 | 9624.60 |
| B | EQUITY AND LIABILITIES | | |
| 1 | Equity | | |
| | -Equity Share Capital | 3753.72 | 3753.72 |
| | -Other Equity | 3192.86 | 2353.84 |
| | Sub-Total "1" Total of Equity | 6946.58 | 6107.56 |
| 2 | Liabilities | | |
| | Non-Current Liabilities | | |
| | <u>Financial Liabilities</u> | | |
| | -Borrowings | 83.04 | 0.00 |
| | -Lease Liabilities | 94.91 | 97.19 |
| | -Other financial liabilities | 0.00 | 0.00 |
| | Provisions | 32.02 | 23.61 |
| | Other non-current liabilities | 0.00 | 0.00 |
| | Sub-Total Non-Current Liabilities | 209.97 | 120.80 |
| | Current Liabilities | | |
| | <u>Financial Liabilities</u> | | |
| | -Borrowings | 3692.12 | 1909.06 |
| | -Lease Liabilities | 2.28 | 2.07 |
| | -Trade Payables | 1931.46 | 1148.84 |
| | -Other Financial Liabilities | 37.68 | 30.23 |
| | Other Current Liabilities | 131.08 | 80.99 |
| | Provisions | 1.69 | 2.87 |
| | Current Tax Liabilities (Net) | 104.11 | 222.18 |
| | Sub-Total Current Liabilities | 5900.42 | 3396.24 |
| | TOTAL EQUITY AND LIABILITIES | 13056.97 | 9624.60 |

Place: Ambala

Dated: 23-05-2025

For and on behalf of the board

(Parmod Kumar)
Managing Director
DIN: 00126965



M. K. PROTEINS LIMITED


Regd. Office: Naraingarh Road, Village Garnala, Ambala City (Haryana), India - 134003

T: 0171-2679358 | W: www.mkproteins.in | E: compliancemkproteins@gmail.com

CIN: L15500HR2012PLC046239 | ISIN: INE964W01013

CASH FLOW STATEMENT FOR THE YEAR ENDED 31ST MARCH 2025

| | PARTICULARS | FOR THE HALF YEAR ENDED 31/03/2025 AUDITED | FOR THE YEAR ENDED 31/03/2024 AUDITED |
|-----------|---|---|--|
| A. | CASH FLOW FROM OPERATING ACTIVITIES | | |
| | -Net Profit/(Loss) before tax | 1145.10 | 1546.97 |
| | -Adjustment for:- | | |
| | Depreciation and amortisation expenses | 35.17 | 52.85 |
| | Interest Expenses | 110.50 | 106.49 |
| | Provision of allowances for Bad and Doubtful debts (Excepted credit loss allowance) | (1.80) | (33.32) |
| | Provision for Retirement Gratuity Benefit to Employees | 4.79 | 3.57 |
| | Net Gain on Sale/Fair Valuation of Investment on FVTPL | (45.86) | (3.62) |
| | Interest Income | 0.00 | (1.03) |
| | Loss on sale of Fixed Assets (Car) | 2.86 | 0.00 |
| | Operating profit before working capital changes | 1250.76 | 1671.91 |
| | Adjustment for (Increase)/Decrease in operating assets: | | |
| | -Trade Receivables | 218.74 | 1281.61 |
| | -Inventories | (3205.24) | (806.75) |
| | -Other Non-Current Assets | (11.06) | (44.98) |
| | -Other Current Assets | (285.92) | 835.52 |
| | Adjustment for Increase/(Decrease) in operating Liabilities: | | |
| | -Trade Payables | 782.62 | 668.60 |
| | -Other Financial Current liabilities | 6.74 | (8.20) |
| | -Other Current Liabilities | 50.09 | (4.77) |
| | -Provisions | 0.00 | 0.00 |
| | Cash use in / generated from operation | (1193.27) | 3592.94 |
| | -Direct taxes paid | (419.52) | (351.32) |
| | NET CASH FROM OPERATING ACTIVITIES | (1612.79) | 3241.62 |
| B. | CASH FLOW FROM INVESTING ACTIVITIES | | |
| | -Sale Proceed of fixed assets | 18.00 | 0.00 |
| | -Sale Proceeds for Investment in Mutual Funds | 1980.86 | 298.62 |
| | -(Increase)/Decrease in Bank Balances not considered as Cash and Cash Equivalent | 0.00 | 0.00 |
| | -Purchase of Investment | (1935.00) | (295.00) |
| | -Fixed Assets/Capital Work in Progress Purchases | (222.33) | (590.33) |
| | -Other Non-Current Financial Asset (Securities) | 10.23 | (2.15) |
| | -Interest Income | 0.00 | 1.03 |
| | NET CASH FROM INVESTING ACTIVITIES | (148.24) | (587.83) |




| | | | | |
|-----------|---|--|----------------|------------------|
| C. | CASH FLOW FROM FINANCING ACTIVITIES | | | |
| | -Increase/(Decrease) in Short term Bank Borrowings | | 1748.70 | (2281.82) |
| | -Increase in Long Term Borrowings | | 133.37 | 0.00 |
| | -Payment of Lease Liabilities | | (12.00) | (12.00) |
| | -Repayment of long term borrowings | | (15.97) | (261.47) |
| | -Finance cost | | (98.92) | (95.52) |
| | NET CASH FROM FINANCING ACTIVITIES | | 1755.18 | (2650.81) |
| | | | | |
| | NET CASH FLOW DURING THE YEAR (A+B+C) | | (5.85) | 2.98 |
| | Cash and Cash Equivalent at beginning of the period | | 9.23 | 6.25 |
| | Cash and Cash Equivalent at end of the period | | 3.38 | 9.23 |

Place: Ambala

Dated: 23-05-2025

For and on behalf of the board

(Parmod Kumar)
Managing Director
DIN: 00126965





M K PROTEINS

23rd May 2025

To
The Manager
Listing Compliance
Bombay Stock Exchange Limited
P.J.Towers, Dalal Street,
Mumbai-400 001
Maharashtra, India
SCRIP CODE: 543919

To
The Manager
Listing Compliance
National Stock Exchange of India
Limited (NSE)
Exchange Plaza, Bandra Kurla
Complex, Bandra East, Mumbai -
400051
NSE SYMBOL: MKPL

Sub: Submission of details of Outstanding Qualified Borrowings and Incremental Qualified Borrowings for the Financial Year ending March 31, 2025.

Ref.: SEBI Operational Circular No. SEBI/HO/DDHS/DDHS-RACPOD1/P/CIR/2023/172 dated October 19, 2023

Dear Sir/Madam,

With reference to the above-mentioned circular please find the details of Outstanding Qualified Borrowings and Incremental Qualified Borrowings for the Financial Year ending March 31, 2025.

| S. No. | Particulars | Details | |
|--------|--|--|--------|
| 1. | Name of the Company | M K Proteins Limited | |
| 2. | CIN | L15500HR2012PLC046239 | |
| 3. | Outstanding borrowing of company as on 31 st March 2024 (in Rs. Crore) | 19.09 Crores | |
| 4. | Outstanding borrowing of company as on 31 st March 2025 (in Rs. Crore) | 37.75 Crores | |
| 5. | Highest credit rating during the previous FY along with name of the Credit Rating Agency | Facilities | Rating |
| | | Long Term Bank Facilities | A |
| | | Short Term Bank Facilities (Cash Credit) | A |
| | | | |
| | | Rating Agency-CRISIL | |

M. K. Proteins Limited

Naraingarh Road, Village Garnala, Ambala City(Haryana), India - 134003

T : 0171-2679358 I W: www.mkproteins.in I E: compliancemkproteins@gmail.com

CIN : L15500HR2012PLC046239| ISIN : INE964W01021



| | | |
|----|--|--------------|
| 6. | Incremental borrowings done during the year (qualified borrowings) (Rs. In Crores) | 18.66 Crores |
| 7. | Borrowings by way of issuance of debt securities during the year (Rs. In Crores) | NIL |

We confirm that we are not a Large Corporate as per the applicability criteria given under the SEBI Circular No. SEBI/HO/DDHS/DDHS-RACPOD1/P/CIR/2023/172 dated October 19, 2023 read with Chapter XII of SEBI Operational circular dated August 10, 2021 (Updated as on April 13, 2022)

The above disclosure shall be taken on record as an enclosure to the Audited Financial Results for the Financial Year ended 31st March 2025.

Thanking You,
Yours Faithfully,
FOR M K PROTEINS LIMITED


Parmod Kumar
Managing Director
DIN: 00126965

